Cited 0 times in
Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, J | - |
dc.contributor.author | Baek, HJ | - |
dc.contributor.author | Noh, E | - |
dc.contributor.author | Yoon, K | - |
dc.contributor.author | Kim, JA | - |
dc.contributor.author | Ryu, S | - |
dc.contributor.author | Lee, KO | - |
dc.contributor.author | Park, NY | - |
dc.contributor.author | Jung, E | - |
dc.contributor.author | Kim, S | - |
dc.contributor.author | Lee, H | - |
dc.contributor.author | Hwang, YS | - |
dc.contributor.author | Jung, J | - |
dc.contributor.author | Lee, HJ | - |
dc.contributor.author | Cho, SI | - |
dc.contributor.author | Oh, S | - |
dc.contributor.author | Kim, M | - |
dc.contributor.author | Oh, CM | - |
dc.contributor.author | Yu, B | - |
dc.contributor.author | Hong, YS | - |
dc.contributor.author | Kim, K | - |
dc.contributor.author | Jung, SJ | - |
dc.contributor.author | Han, MA | - |
dc.contributor.author | Lee, MS | - |
dc.contributor.author | Lee, JJ | - |
dc.contributor.author | Hwangbo, Y | - |
dc.contributor.author | Yim, HW | - |
dc.contributor.author | Kim, YM | - |
dc.contributor.author | Lee, J | - |
dc.contributor.author | Lee, WY | - |
dc.contributor.author | Park, JH | - |
dc.contributor.author | Oh, S | - |
dc.contributor.author | Jo, HS | - |
dc.contributor.author | Kim, H | - |
dc.contributor.author | Kang, G | - |
dc.contributor.author | Nam, HS | - |
dc.contributor.author | Lee, JH | - |
dc.contributor.author | Oh, GJ | - |
dc.contributor.author | Shin, MH | - |
dc.contributor.author | Ryu, S | - |
dc.contributor.author | Hwang, TY | - |
dc.contributor.author | Park, SW | - |
dc.contributor.author | Kim, SK | - |
dc.contributor.author | Seol, R | - |
dc.contributor.author | Park, KS | - |
dc.contributor.author | Kim, SY | - |
dc.contributor.author | Kwon, JW | - |
dc.contributor.author | Kim, SS | - |
dc.contributor.author | Kim, B | - |
dc.contributor.author | Lee, JW | - |
dc.contributor.author | Jang, EY | - |
dc.contributor.author | Kim, AR | - |
dc.contributor.author | Nam, J | - |
dc.contributor.author | Korea Community Health Survey Group | - |
dc.contributor.author | Lee, SY | - |
dc.contributor.author | Kim, DH | - |
dc.date.accessioned | 2023-12-11T05:42:46Z | - |
dc.date.available | 2023-12-11T05:42:46Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/32050 | - |
dc.description.abstract | OBJECTIVES: We estimated the population prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including unreported infections, through a Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) in 258 communities throughout Korea. METHODS: In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling. During face-to-face household interviews, participants self-reported their health status, COVID-19 diagnosis and vaccination history, and general characteristics. Subsequently, participants visited a community health center or medical clinic for blood sampling. Blood samples were analyzed for the presence of antibodies to spike proteins (anti-S) and antibodies to nucleocapsid proteins (anti-N) SARS-CoV-2 proteins using an electrochemiluminescence immunoassay. To estimate the population prevalence, the PROC SURVEYMEANS statistical procedure was employed, with weighting to reflect demographic data from July 2022. RESULTS: In total, 9,945 individuals from 5,041 households were surveyed across 258 communities, representing all basic local governments in Korea. The overall population-adjusted prevalence rates of anti-S and anti-N were 97.6% and 57.1%, respectively. Since the Korea Disease Control and Prevention Agency has reported a cumulative incidence of confirmed cases of 37.8% through July 31, 2022, the proportion of unreported infections among all COVID-19 infection was suggested to be 33.9%. CONCLUSIONS: The K-SEROSMART represents the first nationwide, community-based seroepidemiologic survey of COVID-19, confirming that most individuals possess antibodies to SARS-CoV-2 and that a significant number of unreported cases existed. Furthermore, this study lays the foundation for a surveillance system to continuously monitor transmission at the community level and the response to COVID-19. | - |
dc.language.iso | en | - |
dc.subject.MESH | Antibodies, Viral | - |
dc.subject.MESH | COVID-19 | - |
dc.subject.MESH | COVID-19 Testing | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | SARS-CoV-2 | - |
dc.subject.MESH | Seroepidemiologic Studies | - |
dc.title | Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample | - |
dc.type | Article | - |
dc.identifier.pmid | 37591786 | - |
dc.subject.keyword | Antibody | - |
dc.subject.keyword | Community Health Survey | - |
dc.subject.keyword | COVID-19 | - |
dc.subject.keyword | Sampling studies | - |
dc.subject.keyword | Seroepidemiologic studies | - |
dc.contributor.affiliatedAuthor | Han, J | - |
dc.contributor.affiliatedAuthor | Lee, SY | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.4178/epih.e2023075 | - |
dc.citation.title | Epidemiology and health | - |
dc.citation.volume | 45 | - |
dc.citation.date | 2023 | - |
dc.citation.startPage | e2023075 | - |
dc.citation.endPage | e2023075 | - |
dc.identifier.bibliographicCitation | Epidemiology and health, 45. : e2023075-e2023075, 2023 | - |
dc.identifier.eissn | 2092-7193 | - |
dc.relation.journalid | J020927193 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.